TO Rec'd PCT/PTO

FORM PTO-1390 (Modified) U.S. PATENT AND TRADEMARK OFFICE; U.S. DEPARTMENT OF COMMERCE (REV. 12-2004) ATTORNEY'S DOCKET SGB-101.1 US (8806/94330) TRANSMITTAL LETTER TO THE UNITED STATES U.S. APPLICATION NO. (If known, see 37 CFR 1.5) DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A SUBMISSION UNDER 35 U.S.C. 371 INTERNATIONAL APPLICATION NO. INTERNATIONAL FILING DATE PRIORITY DATE CLAIMED 14 November 2002 PCT/US03/34460 30 October 2003 TITLE OF INVENTION PURIFIED COMPOUNDS THAT INHIBIT INTRACELLULAR 04/PAXILLIN BINDING APPLICANT(S) FOR DO/EO/US Mark Ginsberg and Dale Boger Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information: This is a FIRST submission of items concerning a submission under 35 U.S.C. 371.  $\mathbf{x}$ This is a SECOND or SUBSEQUENT submission of items concerning a submission under 35 U.S.C. 371. 2. This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6),  $\mathbf{x}$ 3. (9) and (24) indicated below. The US has been elected (Article 31). 4. A copy of the International Application as filed (35 U.S.C. 371 (c)(2)) 5. is attached hereto (required only if not communicated by the International Bureau). a. 🛭 b. 🗵 has been communicated by the International Bureau. is not required, as the application was filed in the United States Receiving Office (RO/US). c. 🗆 An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). a. 🗆 is attached hereto. has been previously submitted under 35 U.S.C. 154(d)(4). b. 🗆 Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3)) are attached hereto (required only if not communicated by the International Bureau).  $\boxtimes$ have been communicated by the International Bureau. have not been made; however, the time limit for making such amendments has NOT expired. C. d. 🗖 have not been made and will not be made. An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 8. An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)). 9. An English language translation of the annexes to the International Preliminary Examination Report under PCT 10. Article 36 (35 U.S.C. 371 (c)(5)). A copy of the International Preliminary Examination Report (PCT/IPEA/409). 11. 12. A copy of the International Search Report (PCT/ISA/210). Items 13 to 23 below concern document(s) or information included: An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 13. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 14. 15.  $\boxtimes$ A FIRST preliminary amendment. A SECOND or SUBSEQUENT preliminary amendment. 16. 17. A substitute specification.  $\boxtimes$ A power of attorney and/or change of address letter. 18. 19. A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821 - 1.825. A second copy of the published International Application under 35 U.S.C. 154(d)(4). 20. 21. A second copy of the English language translation of the International Application under 35 U.S.C. 154(d)(4).

Application Data Sheet, Preliminary Amendment and Abstract Page, Response to Communication in Cases for Which No Other Form is

Applicable (correcting claimes) and Verified Certification of Express Mailing (37CFR 1.10(c) No. EV554441954US

 $\boxtimes$ 

Express Mail Label No.

Other items or information:

EV554441954US

22.

23

PTO-1390 (Rev. 12-2004)
Approved for use through 3/31/2007. OMB 0651-0021
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

U.S. APPLICATION NO (if known, see 37 CFR 1.5)			INTERNATIONAL APPLICATION NO.			ATTORNEY'S DOCKET NUMBER					
104535017			PCT/US03/34460			SGB-101.1 US (94330)					
24. The following fees are submitted:							App	olicant use	Office use		
☐ a) Basic national fee							\$	\$300.00			
⊠ b) Examination fee							\$	\$200.00			
⊠ c) Search fee							\$	\$500.00			
TOTAL OF ABOVE CALCULATIONS = \$1000.00							\$	\$1,000.00			
Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing or computer program listing filed in an electronic medium). The fee is \$250 for each additional 50 sheets of paper or fraction thereof.											
Total Sheets	Extra Sheets										
75 - 100 =	0 /50 =		0		x		\$	\$0.00	,		
Surcharge of \$130.00 for furnishing the oath or declaration later than months from the earliest claimed priority date (37 CFR 1.492(e)).							\$	\$130.00			
CLAIMS	NUMBER F	ILED N	NUMBER EXTRA		RATE						
Total claims	32	- 20 =	12	x	\$50	0.00	\$	\$600.00			
Independent clai	ms 4	- 3=	1	×	\$200	0.00	\$	\$200.00			
MULTIPLE DEP	ENDENT CLAIMS	(if applicable)		+			\$	\$0.00			
			L OF ABOVE C				\$	\$1,930.00			
		tatus. See 37	CFR 1.27. The fees	indica	ted above	are	\$	\$965.00			
					UBTOT		\$	\$965.00			
Processing fee of the earliest claim	f \$130.00 for furnised priority date (3	shing the Engl	ish translation later t f)).	han 30	0 months fi	rom	\$	\$0.00			
		,	TOTAL I	NATI	ONAL F	EE =	\$	\$965.00			
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40 per property +						\$	\$0.00				
TOTAL FEES ENCLOSED =							\$	\$965.00			
Amount to be refunded:						ided:			s		
Amount to be charged:									\$		
a. 🛛 A check	in the amount of \$	\$965.0	0 to cover the	above	fees is en	closed			I		
b. Dease	charge my Deposit		23-0920	in the	amount of			to cover the above fees.			
c. 🛛 The Dire	The Director is hereby authorized to charge any additional fees which may be required, or credit any overpayment										
<ul> <li>to Deposit Account No. 23-0920 . A duplicate copy of this sheet is enclosed.</li> <li>d. Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.</li> </ul>											
NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the International Application to pending status.								.137(a) or (b))			
SEND ALL CORRESPONDENCE TO:						19	To the same	<i></i>			
Edward P. Gamson, Esq. SIGNATUF WELSH & KATZ, LTD. Edward								_			
120 South Rive			Edwa	Edward P. Gamson, Esq.							
22nd Floor NAME											
Chicago, Illiniois 60606 29,381											
					REGI	STRAT	ΓΙΟΝ	NUMBER			

10/535017 PTO 12 MAY 2005

Attorney's Docket No30	JC14 Rec'd PCT/PTO 12 MAY 2					
	RECEIVING OFFICE (RO/US					
IN THE UNITED STATES	DESIGNATED OFFICE (DO/US)					
X	ELECTED OFFICE (EO/US)					
	per 2003 14 November 2002 ALFILING DATE PRIORITY DATE CLAIMED					
INTERNATIONAL APPLICATION NO. INTERNATION.	AL FILING DATE PRIORITY DATE CLAIMED					
PURIFIED COMPOUNDS THAT INHIBIT INTRACE	LLULAR α4/PAXILLIN BINDING					
Mark Ginsherg and Dale Boger APPLICANT(s)						
Box PCT U.S. Patent and Trademark Office P.O. Box 2327 Arlington, VA 22202						
	OF EXPRESS MAILING DATE ICATION (37 CFR 1.10(c))					
"Express Mail, Post Office to Addressee" bearing La	n the United States Postal Service in an envelope as bel Number <u>EV554441954US</u> addressed to "Box 327, Arlington, VA 22202" and having an express mail					
	application including spec claims and abstract and					
drawings, Decl. and Power of Attorney documents, Ap	plication Data Sheet, Search, Preliminary Amendment					
and Abstract Page, Response to Communication in Ca	ases for Which No Other Form is Applicable (correcting					
claimes) and Application Fee						
A copy of these papers from the file of this application	n is attached.					
on information and belief are believed to be true; are knowledge that willful false statements and the like so	own knowledge are true and that all statements made and further that these statements were made with the made are punishable by fine or imprisonment, or both, s Code, and that such willful false statements may ssuing thereon.					
	nnon Wooten d or printed name of person making this verified statement)					

(Signature of person making this verified statement)

Date May 12, 2005





## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE UNITED STATES RECEIVING OFFICE (RO/US)

Applicant:	The Scripps Research Institute et al.	,							
International Application No. PCT/US03/34460									
Internatio Filing Dat	nal e: 30 October 2003								
Title:	PURIFIED COMPOUNDS THAT INHIBIT INTRACELLULAR α4/PAXILLIN BINDING	)							

## RESPONSE TO COMMUNICATION IN CASES FOR WHICH NO OTHER FORM IS APPLICABLE

Mail Stop PCT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

This is in response to the Communication in Cases For Which No Other Form Is Applicable dated 5
February 2004, indicating a discrepancy concerning the claims in the international application.

Transmitted herewith is a red-marked copy of page 62 of the claims where claim No. 13 is missing.

Also transmitted herewith are replacement claims (pages 58-68) correcting the claim numbers to include claim

No. 13 and renumbering them from 1-31.





10/535017 JC14 PCT/PTO 12 MAY 2005

International Application -2-No. PCT/US03/34460

No fee is believed necessary. However, please charge our Deposit Account No. 23-0920 should any fee be needed.

The Examiner is requested to phone the undersigned should any questions arise that can be dealt with over the phone to expedite this prosecution.

Respectfully submitted,

Edward P. Gamson, Reg.No. 29,381

Enclosures:

Red-marked copy of page 62 of claims Replacement Claims (pages 58-68)

WELSH & KATZ, LTD. 120 South Riverside Plaza, 22nd Floor Chicago, Illinois 60606 Phone (312) 655-1500 Fax No. (312) 655-1501





International Application -3-No. PCT/US03/34460

## CERTIFICATE OF MAILING BY EXPRESS MAIL

I hereby certify that this Response, together with the stated enclosures, are being deposited with the United States Postal Service as Express Mail, Express Mail Mailing Label No. EV337100402US addressed to Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on February 24, 2004.

John Austin Rensert